When Should Pharmacological Interventions for Insomnia Be Recommended?
AMA Journal of Ethics · 2024
DOI: 10.1001/amajethics.2024.763 ↗Kurz gefasst
Fallbericht in der Zeitschrift AMA Journal of Ethics, 2024. Verfasst von Brandon Peters und 1 weiteren Autor:innen. Beteiligte Einrichtung: Double-board-certified neurologist and sleep medicine physician at Virginia Mason Franciscan Health in Seattle, Washington. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Cognitive Behavioral Therapy, Hypnotics and Sedatives.
Themen: Schlaf
Abstract (Originalsprache)
This commentary on a case describes how social determinants of health also contribute to insomnia and then suggests how to balance risks and benefits of different strategies for managing chronic insomnia. Behaviorally induced insufficient sleep syndrome can exacerbate morning side effects of prescription sleep aids, and there are potentially serious long-term risks (eg, dementia, falls, death) associated with chronic benzodiazepine use. Before trying sleeping pills, chronic insomnia should be treated with cognitive behavioral therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Double-board-certified neurologist and sleep medicine physician at Virginia Mason Franciscan Health in Seattle, Washington.
- Second-year internal medicine resident at Virginia Mason Medical Center in Seattle, Washington.
Zitieren
APA
Peters, B., & Sarver, M. (2024). When Should Pharmacological Interventions for Insomnia Be Recommended?. AMA Journal of Ethics. https://doi.org/10.1001/amajethics.2024.763
Vancouver
Peters B, Sarver M. When Should Pharmacological Interventions for Insomnia Be Recommended?. AMA Journal of Ethics. 2024. doi:10.1001/amajethics.2024.763
BibTeX
@article{Peters2024,
author = {Peters, Brandon and Sarver, Maxwell},
title = {When Should Pharmacological Interventions for Insomnia Be Recommended?},
journal = {AMA Journal of Ethics},
year = {2024},
doi = {10.1001/amajethics.2024.763}
}
EUVIMED